DOP2011000325A - Composición farmacéutica en forma de una solución líquida que comprende n- (4-(4-((2-(4-clorofenil)-5,5-dimetil-1-ciclohex-1-en-1-il)metil)piperazin-1-il)benzoil)-4- (((1r)-3-(morfolin-4-il)-1-((fenilsulfanil)metil)propil)amino-3-((trifluorometil) sulfonil)bencenosulfonamida (abt-263) - Google Patents
Composición farmacéutica en forma de una solución líquida que comprende n- (4-(4-((2-(4-clorofenil)-5,5-dimetil-1-ciclohex-1-en-1-il)metil)piperazin-1-il)benzoil)-4- (((1r)-3-(morfolin-4-il)-1-((fenilsulfanil)metil)propil)amino-3-((trifluorometil) sulfonil)bencenosulfonamida (abt-263)Info
- Publication number
- DOP2011000325A DOP2011000325A DO2011000325A DO2011000325A DOP2011000325A DO P2011000325 A DOP2011000325 A DO P2011000325A DO 2011000325 A DO2011000325 A DO 2011000325A DO 2011000325 A DO2011000325 A DO 2011000325A DO P2011000325 A DOP2011000325 A DO P2011000325A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- cancer
- methyl
- pharmaceutical composition
- bcl
- abt
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000006193 liquid solution Substances 0.000 title abstract 2
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 title abstract 2
- 229950004847 navitoclax Drugs 0.000 title abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 2
- GEAXLHPORCRESC-UHFFFAOYSA-N chlorocyclohexatriene Chemical class ClC1=CC=C=C[CH]1 GEAXLHPORCRESC-UHFFFAOYSA-N 0.000 title 1
- 201000011510 cancer Diseases 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 2
- -1 (trifluoromethyl) sulfonyl Chemical group 0.000 abstract 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 abstract 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 abstract 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 abstract 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 abstract 1
- 208000003445 Mouth Neoplasms Diseases 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 abstract 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 abstract 1
- 208000000277 Splenic Neoplasms Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 201000006491 bone marrow cancer Diseases 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 201000003444 follicular lymphoma Diseases 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 210000005265 lung cell Anatomy 0.000 abstract 1
- 208000003747 lymphoid leukemia Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 208000025113 myeloid leukemia Diseases 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 abstract 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 201000002471 spleen cancer Diseases 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composición farmacéutica en forma de una solución líquida que comprende N-(4-(4-((2-(4-clorofenil)-5,5-dimetil-1-ciclohex-1-en-1-il)metil)piperazin-1- il)benzoil)-4-(((1R)-3-(morfolin-4-il)-1-((fenilsulfanil)metil)propil)amino-3-((trifluorometil) sulfonil)bencenosulfonamida (ABT-263), el cual tiene la siguiente fórmula: Esta composición farmacéutica es adecuada para administración oral a un sujeto que necesita un tratamiento de una enfermedad caracterizada por la sobreexpresión de una o más proteínas Bcl-2 Bcl-w o Bcl-2, tales como por ejemplo el cáncer, cáncer de vejiga, cáncer de cerebro,cáncer de mama, cáncer de médula osea, cáncer cervical, leucemia linfocítica crónica, leucemia linfocítica aguda, cáncer colorectal, cáncer de esófago, cáncer hepatocelular, leucemia linfoblástica, linfoma folicular, tumores malignos originados en las células T o en las células B, melanoma, leucemia mielógena, mieloma, cáncer oral, cáncer de ovario, cáncer de células pulmonares no pequeñas, cáncer de próstata, cáncer de la células pulmonares pequeñas o cáncer de bazo, entre otras
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17429909P | 2009-04-30 | 2009-04-30 | |
US28925409P | 2009-12-22 | 2009-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2011000325A true DOP2011000325A (es) | 2011-11-15 |
Family
ID=42732293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2011000325A DOP2011000325A (es) | 2009-04-30 | 2011-10-25 | Composición farmacéutica en forma de una solución líquida que comprende n- (4-(4-((2-(4-clorofenil)-5,5-dimetil-1-ciclohex-1-en-1-il)metil)piperazin-1-il)benzoil)-4- (((1r)-3-(morfolin-4-il)-1-((fenilsulfanil)metil)propil)amino-3-((trifluorometil) sulfonil)bencenosulfonamida (abt-263) |
Country Status (24)
Country | Link |
---|---|
US (1) | US8728516B2 (es) |
EP (1) | EP2424499A1 (es) |
JP (1) | JP5788869B2 (es) |
KR (1) | KR20120027283A (es) |
CN (1) | CN102802605B (es) |
AR (1) | AR076511A1 (es) |
AU (1) | AU2010242926B2 (es) |
BR (1) | BRPI1014492A8 (es) |
CA (1) | CA2758596A1 (es) |
CL (1) | CL2011002652A1 (es) |
CO (1) | CO6470833A2 (es) |
DO (1) | DOP2011000325A (es) |
EC (1) | ECSP11011491A (es) |
IL (1) | IL215474A (es) |
MX (1) | MX2011011525A (es) |
MY (1) | MY160603A (es) |
NZ (1) | NZ596047A (es) |
PE (1) | PE20120642A1 (es) |
RU (1) | RU2530642C2 (es) |
SG (1) | SG175145A1 (es) |
TW (2) | TW201100125A (es) |
UY (1) | UY32601A (es) |
WO (1) | WO2010127193A1 (es) |
ZA (1) | ZA201107594B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100280031A1 (en) * | 2009-04-30 | 2010-11-04 | Paul David | Lipid formulation of apoptosis promoter |
US8362013B2 (en) * | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
US8728516B2 (en) | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
TWI540132B (zh) * | 2009-06-08 | 2016-07-01 | 亞培公司 | Bcl-2族群抑制劑之口服醫藥劑型 |
JP2013505249A (ja) | 2009-09-20 | 2013-02-14 | アボット・ラボラトリーズ | Bcl−2タンパク質関連疾患の治療における使用のためのABT−263結晶形態および溶媒和物 |
CA2780177A1 (en) * | 2009-12-22 | 2011-06-30 | Abbott Laboratories | Abt-263 capsule |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
US8716363B2 (en) | 2011-09-28 | 2014-05-06 | Globus Medical, Inc. | Biodegradable putty compositions and implant devices, methods, and kits relating to the same |
CN111956646B (zh) * | 2016-03-02 | 2023-07-25 | 麦迪维尔股份公司 | 索拉非尼或瑞戈非尼与曲沙他滨的氨基磷酸酯前药的组合治疗 |
CN112552348B (zh) * | 2019-09-26 | 2023-03-17 | 北京桦冠生物技术有限公司 | 含硒化合物及其制备和应用 |
AU2020380404A1 (en) * | 2019-11-08 | 2022-06-09 | Retina Foundation Of The Southwest | Compounds and implants for treating ocular disorders |
CN110963954A (zh) * | 2019-12-16 | 2020-04-07 | 武汉轻工大学 | 一种硒代蛋氨酸衍生物的合成方法及硒代蛋氨酸制品 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5665379A (en) * | 1990-09-28 | 1997-09-09 | Pharmacia & Upjohn Aktiebolag | Lipid particle forming matrix, preparation and use thereof |
IL111004A (en) * | 1993-09-30 | 1998-06-15 | American Home Prod | Oral formulations of rapamycin |
US5536729A (en) * | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
JPH09510182A (ja) * | 1993-11-17 | 1997-10-14 | エルディーエス・テクノロジーズ・インコーポレーテッド | カプセル封入されたドラッグデリバリー用透明液 |
US5759548A (en) * | 1993-11-30 | 1998-06-02 | Lxr Biotechnology Inc. | Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US5538737A (en) * | 1994-11-30 | 1996-07-23 | Applied Analytical Industries, Inc. | Oral compositions of H2 -antagonists |
FR2736550B1 (fr) * | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
BE1011899A6 (fr) * | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
DE19913692A1 (de) | 1999-03-25 | 2000-09-28 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
DE19929361A1 (de) | 1999-06-25 | 2001-01-04 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
US20060183776A9 (en) * | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
US6720338B2 (en) * | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
US20020055631A1 (en) * | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
UY26942A1 (es) | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
OA12541A (en) * | 2001-01-31 | 2006-06-05 | Pfizer Prod Inc | Ether derivatives useful as inhibitors of PDE4 isozymes. |
US20030105144A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
ATE464880T1 (de) * | 2002-02-04 | 2010-05-15 | Elan Pharma Int Ltd | Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator |
AU2003208444B2 (en) * | 2002-02-26 | 2006-10-26 | Astrazeneca Ab | Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
PE20030828A1 (es) * | 2002-03-04 | 2003-11-04 | Novartis Ag | Composicion oftalmica que comprende ascomicina |
US7030115B2 (en) * | 2002-03-21 | 2006-04-18 | Abbott Laboratories | N-sulfonylurea apoptosis promoters |
MY129850A (en) * | 2002-04-29 | 2007-05-31 | Merck Sharp & Dohme | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
CA2810477C (en) * | 2002-12-13 | 2013-09-17 | Durect Corporation | Oral drug delivery system |
US20060177430A1 (en) * | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
US7790190B2 (en) * | 2004-03-20 | 2010-09-07 | Yasoo Health, Inc. | Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid |
FR2875409B1 (fr) * | 2004-09-17 | 2010-05-07 | Sanofi Aventis | Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose |
AU2006297853B2 (en) * | 2005-05-12 | 2010-08-19 | AbbVie Global Enterprises Ltd. | Apoptosis promoters |
CN1706371B (zh) | 2005-05-27 | 2010-11-10 | 沈阳药科大学 | 一种高效的马蔺子素制剂及其制备方法 |
ES2385513T3 (es) | 2005-10-11 | 2012-07-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Composición para administración nasal |
WO2007050574A1 (en) * | 2005-10-25 | 2007-05-03 | Abbott Laboratories | Formulation comprising a drug of low water solubility and method of use thereof |
US20080085313A1 (en) * | 2006-05-15 | 2008-04-10 | Given Bruce D | Methods and compositions for treatment of sleep apnea |
EP1880715A1 (en) | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
CN101534904B (zh) * | 2006-09-05 | 2013-11-06 | Abbvie公司 | 治疗血小板过量的bcl抑制剂 |
JP2010504974A (ja) * | 2006-09-28 | 2010-02-18 | フォリカ,インコーポレーテッド | 新しい毛嚢を生成させ毛髪を成長させる方法、キット、及び組成物 |
WO2008064116A2 (en) * | 2006-11-16 | 2008-05-29 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
WO2008124878A1 (en) | 2007-04-13 | 2008-10-23 | Cryptopharma Pty Ltd | Non-steroidal compounds |
JP2011500569A (ja) * | 2007-10-12 | 2011-01-06 | マサチューセッツ インスティテュート オブ テクノロジー | ワクチンナノテクノロジー |
US20090098118A1 (en) * | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
JP2011506338A (ja) * | 2007-12-06 | 2011-03-03 | アボット・ラボラトリーズ | 癌の治療のためのabt−263の経口用組成物 |
CN101220008B (zh) | 2008-01-21 | 2011-04-27 | 中国科学院广州生物医药与健康研究院 | 化合物abt-263的合成方法 |
US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
US8362013B2 (en) | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
US20100297194A1 (en) | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
US8728516B2 (en) | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
US20100278921A1 (en) * | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
MX2011013797A (es) * | 2009-06-18 | 2012-01-30 | Abbott Lab | Suspension de farmaco estable de nanoparticula. |
JP2013505249A (ja) | 2009-09-20 | 2013-02-14 | アボット・ラボラトリーズ | Bcl−2タンパク質関連疾患の治療における使用のためのABT−263結晶形態および溶媒和物 |
CN101798292A (zh) | 2010-03-29 | 2010-08-11 | 无锡好芳德药业有限公司 | ABT-263衍生的新型Bcl-2蛋白抑制剂的制备 |
-
2010
- 2010-04-29 US US12/770,174 patent/US8728516B2/en not_active Expired - Fee Related
- 2010-04-30 RU RU2011148516/15A patent/RU2530642C2/ru not_active IP Right Cessation
- 2010-04-30 AU AU2010242926A patent/AU2010242926B2/en not_active Ceased
- 2010-04-30 BR BRPI1014492A patent/BRPI1014492A8/pt not_active IP Right Cessation
- 2010-04-30 CA CA2758596A patent/CA2758596A1/en not_active Abandoned
- 2010-04-30 WO PCT/US2010/033075 patent/WO2010127193A1/en active Application Filing
- 2010-04-30 UY UY0001032601A patent/UY32601A/es not_active Application Discontinuation
- 2010-04-30 MX MX2011011525A patent/MX2011011525A/es active IP Right Grant
- 2010-04-30 NZ NZ596047A patent/NZ596047A/xx not_active IP Right Cessation
- 2010-04-30 KR KR1020117028613A patent/KR20120027283A/ko not_active Application Discontinuation
- 2010-04-30 TW TW099113990A patent/TW201100125A/zh unknown
- 2010-04-30 TW TW104144761A patent/TW201628601A/zh unknown
- 2010-04-30 EP EP10717961A patent/EP2424499A1/en not_active Withdrawn
- 2010-04-30 MY MYPI2011005143A patent/MY160603A/en unknown
- 2010-04-30 SG SG2011073624A patent/SG175145A1/en unknown
- 2010-04-30 CN CN201080029687.1A patent/CN102802605B/zh not_active Expired - Fee Related
- 2010-04-30 JP JP2012508759A patent/JP5788869B2/ja not_active Expired - Fee Related
- 2010-04-30 PE PE2011001864A patent/PE20120642A1/es not_active Application Discontinuation
- 2010-04-30 AR ARP100101469A patent/AR076511A1/es unknown
-
2011
- 2011-10-02 IL IL215474A patent/IL215474A/en not_active IP Right Cessation
- 2011-10-17 ZA ZA2011/07594A patent/ZA201107594B/en unknown
- 2011-10-25 DO DO2011000325A patent/DOP2011000325A/es unknown
- 2011-10-25 CL CL2011002652A patent/CL2011002652A1/es unknown
- 2011-11-25 CO CO11162226A patent/CO6470833A2/es active IP Right Grant
- 2011-11-29 EC EC2011011491A patent/ECSP11011491A/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL215474A (en) | 2015-06-30 |
CO6470833A2 (es) | 2012-06-29 |
JP2012525435A (ja) | 2012-10-22 |
AR076511A1 (es) | 2011-06-15 |
KR20120027283A (ko) | 2012-03-21 |
MX2011011525A (es) | 2011-11-18 |
AU2010242926A1 (en) | 2011-11-10 |
ECSP11011491A (es) | 2011-12-30 |
AU2010242926B2 (en) | 2014-04-24 |
RU2011148516A (ru) | 2013-06-10 |
MY160603A (en) | 2017-03-15 |
ZA201107594B (en) | 2014-03-26 |
JP5788869B2 (ja) | 2015-10-07 |
US20100278905A1 (en) | 2010-11-04 |
PE20120642A1 (es) | 2012-06-24 |
SG175145A1 (en) | 2011-11-28 |
US8728516B2 (en) | 2014-05-20 |
BRPI1014492A2 (pt) | 2016-04-05 |
BRPI1014492A8 (pt) | 2017-10-24 |
TW201100125A (en) | 2011-01-01 |
TW201628601A (zh) | 2016-08-16 |
IL215474A0 (en) | 2011-12-29 |
EP2424499A1 (en) | 2012-03-07 |
UY32601A (es) | 2010-12-31 |
CN102802605B (zh) | 2015-08-12 |
RU2530642C2 (ru) | 2014-10-10 |
NZ596047A (en) | 2013-11-29 |
CA2758596A1 (en) | 2010-11-04 |
CL2011002652A1 (es) | 2012-04-20 |
CN102802605A (zh) | 2012-11-28 |
WO2010127193A1 (en) | 2010-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2011000325A (es) | Composición farmacéutica en forma de una solución líquida que comprende n- (4-(4-((2-(4-clorofenil)-5,5-dimetil-1-ciclohex-1-en-1-il)metil)piperazin-1-il)benzoil)-4- (((1r)-3-(morfolin-4-il)-1-((fenilsulfanil)metil)propil)amino-3-((trifluorometil) sulfonil)bencenosulfonamida (abt-263) | |
DOP2012000153A (es) | Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cancer y enfermedades inmunes | |
DOP2012000154A (es) | COMPUESTOS N-ACILSULFONAMIDA QUE INHIBEN LA ACTIVIDAD DE LAS PROTEINAS ANTIAPOPTOTICAS Bcl2 Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CANCER Y DE ENFERMEDADES INMUNES Y AUTOINMUNES | |
DOP2012000298A (es) | Compuestos inductores de la apoptosis derivados de sulfonil carbamoil-fenoxi pirrolopiridina, útiles en el tratamiento del cancer y de enfermedades inmunes y autoinmunes | |
NZ593593A (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
CY1120619T1 (el) | Χημικες οντοτητες | |
DOP2011000367A (es) | DERIVADOS DE SULFONAMIDA SUSTITUIDA CON 1H-PIRROLO[2,3,b]PIRIDIN-5-ILOXI COMO AGENTES INDUCTORES DE APOPTOSIS PARA EL TRATAMIENTO DE CANCER Y ENFERMEDADES INMUNES Y AUTOINMUNES | |
IL260297A (en) | Process for preparing n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino )–benzamide | |
CL2017001249A1 (es) | Forma cristalina de sulfato de hidrógeno (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidinaa-1-il)-pirazolo[1,5-a] pirimidinaa-3-il)-3-hidroxipirrolidinaa-1-carboxamida. | |
MX2010006260A (es) | Composiciones orales de abt-263 para tratar cancer. | |
EA201391470A1 (ru) | Замещенные соли 2,3-дигидроимидазо[1,2-c]хиназолина | |
TR201901312T4 (tr) | Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri. | |
NZ561609A (en) | 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters | |
PE20051096A1 (es) | Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida | |
BR112012027743A2 (pt) | ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas | |
TN2018000119A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
CL2014000746A1 (es) | Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer. | |
NZ598461A (en) | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases | |
CU20120169A7 (es) | Compuestos pirimidinílicos como inhibidores de la cinasa atr | |
EA202090860A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
UA112795C2 (uk) | Біциклічні піразинонові похідні | |
CL2008003200A1 (es) | Compuestos derivados de tiazol, inhibidores de la proteina quinasas; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de vejiga, de mama y de rinon. | |
TW201613864A (en) | Novel compounds | |
TN2015000313A1 (en) | Chemical compounds | |
EA201492004A1 (ru) | Органические композиции для лечения kras-ассоциированных заболеваний |